Literature DB >> 21125283

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis.

Vidya S Limaye1, Sue Lester, Peter Bardy, Philip Thompson, Sally Cox, Peter Blumbergs, Peter Roberts-Thomson.   

Abstract

The aim of this study was to determine the HLA and autoantibody associations of patients with histologically confirmed idiopathic inflammatory myositis (IIM). Serum and DNA were archived from South Australian patients with biopsy-proven dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM). HLA typing for Class I and II alleles was performed by serology and DNA-based technology, respectively, for 133 myositis patients and 166 Caucasian population-based controls. Myositis-specific and myositis-associated autoantibodies were detected by line immunoblot. All alleles of the 8.1AH were associated with myositis susceptibility. The B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups. Autoantibodies were present in 42/130 (32%) IIM patients and were more frequent in DM (11/17, 65%) than PM (23/70, 33%) or IBM (8/43, 19%), P = 0.002. Autoantibodies were associated with DRB1 03 (P = 0.0005) but also with DRB1 04 (P = 0.004). The frequency of autoantibodies in the three myositis subgroups mirrored the frequency of DR4. Polyarthralgiasynovitis) was more common in DM/PM (30/76, 39%) than IBM (3/32, 9%), P = 0.004, and there was a strong ordinal association between the prevalence of autoantibodies and polyarthralgia ± synovitis (proportional OR = 5.5, 95% CI 2.3-13.7, P = 0.0004). The central MHC region confers the strongest susceptibility for IIM and also modulates disease phenotype. Our findings reveal a novel association of autoantibodies with DR4 and with arthralgia/synovitis in IIM and raise the possibility of a genetically (DR4) determined citrullination of myositis autoantigens expressed in muscle and synovium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125283     DOI: 10.1007/s00296-010-1637-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  43 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Analysis of HLA class I and II alleles in sporadic inclusion-body myositis.

Authors:  Johannes B Lampe; Gudrun Gossrau; Andrea Kempe; Monika Füssel; Katja Schwurack; Rolf Schröder; Sabine Krause; Ralf Kohnen; Maggie C Walter; Heinz Reichmann; Hanns Lochmüller
Journal:  J Neurol       Date:  2003-11       Impact factor: 4.849

Review 3.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

4.  Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase.

Authors:  Michito Hirakata; Akira Suwa; Tetsuya Takada; Shinji Sato; Sonoko Nagai; Ekkehard Genth; Yeong W Song; Tsuneyo Mimori; Ira N Targoff
Journal:  Arthritis Rheum       Date:  2007-04

5.  Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis.

Authors:  Yoshioki Yamasaki; Hidehiro Yamada; Toshiko Nozaki; Jun Akaogi; Cody Nichols; Robert Lyons; Anthony Chin Loy; Edward K L Chan; Westley H Reeves; Minoru Satoh
Journal:  Arthritis Rheum       Date:  2006-06

6.  Clinical implications of autoantibody screening in patients with autoimmune myositis.

Authors:  A Ghirardello; S Zampieri; E Tarricone; L Iaccarino; R Bendo; C Briani; R Rondinone; P Sarzi-Puttini; S Todesco; A Doria
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

7.  A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity.

Authors:  D Lio; G Candore; A Colombo; G Colonna Romano; F Gervasi; V Marino; L Scola; C Caruso
Journal:  Hum Immunol       Date:  2001-07       Impact factor: 2.850

8.  Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis.

Authors:  Ejaz A Shamim; Lisa G Rider; Janardan P Pandey; Terrance P O'Hanlon; Luis J Jara; Eduardo A Samayoa; Ruben Burgos-Vargas; Janitzia Vazquez-Mellado; Jorge Alcocer-Varela; Mario Salazar-Paramo; Abraham Garcia Kutzbach; James D Malley; Ira N Targoff; Ignacio Garcia-De la Torre; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2002-07

9.  Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.

Authors:  Z E Betteridge; H Gunawardena; H Chinoy; J North; W E R Ollier; R G Cooper; N J McHugh
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103

Review 10.  Idiopathic inflammatory myopathies.

Authors:  V S Limaye; P Blumbergs; P J Roberts-Thomson
Journal:  Intern Med J       Date:  2009-03       Impact factor: 2.048

View more
  5 in total

1.  Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.

Authors:  Michael J Waters; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

2.  The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis.

Authors:  Vidya Limaye; Colin Luke; Graeme Tucker; Catherine Hill; Susan Lester; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Rheumatol Int       Date:  2012-07-26       Impact factor: 2.631

3.  Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies.

Authors:  Adam Maundrell; Susanna Proudman; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-08-05       Impact factor: 2.631

4.  Autoantibodies against a 43 KDa muscle protein in inclusion body myositis.

Authors:  Mohammad Salajegheh; Theresa Lam; Steven A Greenberg
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

5.  Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort.

Authors:  Angeles S Galindo-Feria; Begum Horuluoglu; Jessica Day; Catia Fernandes-Cerqueira; Edvard Wigren; Susanne Gräslund; Susanna Proudman; Ingrid E Lundberg; Vidya Limaye
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.